UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~June~~September 30, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to ______________________

COMMISSION FILE NUMBER: 001-38365

EYENOVIA, INC.
(Exact name of Registrant as Specified in Its Charter)

DELAWARE		47-1178401
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

295 Madison Avenue, Suite 2400 NEW YORK, NY		10017
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (917) 289-1117

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 Par Value	EYEN	Nasdaq Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨

Non-accelerated filer x	Smaller reporting company x

	Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any news or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

The number of outstanding shares of the registrant’s common stock was ~~20,536,431~~24,884,251 as of ~~August 13,~~November 10, 2020.

EYENOVIA, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~JUNE~~SEPTEMBER 30, 2020

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.		2

Condensed Balance Sheets as of
~~June~~ September 30, 2020 (Unaudited) and December 31, 2019		2

Unaudited Condensed Statements of Operations for the ~~three~~Three and
~~Six~~ Nine Months Ended ~~June~~September 30, 2020 and 2019		3

Unaudited Condensed Statements of Changes in Stockholders' Equity for the
~~Six~~ Nine Months Ended ~~June~~September 30, 2020 and 2019		4

Unaudited Condensed Statements of Cash Flows for the
~~Six~~ Nine Months Ended ~~June~~September 30, 2020 and 2019		5

Notes to Unaudited Condensed Financial Statements		6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.		1619

Item 3. Quantitative and Qualitative Disclosures About Market Risk.		2023

Item 4. Controls and Procedures.		2023

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.		2125

Item 1A. Risk Factors.		2125

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.		2125

Item 3. Defaults Upon Senior Securities.		2125

Item 4. Mine Safety Disclosures.		2125

Item 5. Other Information.		2125

Item 6. Exhibits.		2226

SIGNATURES		2327

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

EYENOVIA, INC.

Condensed Balance Sheets

	June 30,			December 31,
	2020			2019			September 30,			December 31,
	(unaudited)						2020			2019
							(unaudited)
Assets

Current Assets:
Cash	$	10,186,171		$	14,152,601
Cash and cash equivalents							$	22,864,578		$	14,152,601
Deferred license costs								1,600,000			-
Prepaid expenses and other current assets		809,083			196,680			903,090			196,680

Total Current Assets		10,995,254			14,349,281			25,367,668			14,349,281

Property and equipment, net		313,438			230,538			360,956			230,538
Security deposit		119,035			117,800			119,035			117,800

Total Assets	$	11,427,727		$	14,697,619		$	25,847,659		$	14,697,619

Liabilities and Stockholders' Equity

Current Liabilities:
Accounts payable	$	1,078,700		$	1,541,358		$	1,464,762		$	1,541,358
Accrued compensation		573,906			916,873			744,555			916,873
Accrued expenses and other current liabilities		681,225			453,430			373,609			453,430
Deferred rent - current portion								7,809			-
Deferred license fee								4,000,000			-
Notes payable - current portion		421,599			-			145,942			-

Total Current Liabilities		2,755,430			2,911,661			6,736,677			2,911,661

Deferred rent		45,345			45,351
Deferred rent - non-current portion								36,423			45,351
Notes payable - non-current portion		307,646			-			424,338			-

Total Liabilities		3,108,421			2,957,012			7,197,438			2,957,012

Commitments and contingencies (Note 7)

Stockholders' Equity:
Preferred stock, $0.0001 par value, 6,000,000 shares authorized;
0 shares issued and outstanding as of June 30, 2020 and
0 shares issued and outstanding as of September 30, 2020 and
as of December 31, 2019		-			-			-			-
Common stock, $0.0001 par value, 90,000,000 shares authorized;
19,943,683 and 17,100,726 shares issued and outstanding
as of June 30, 2020 and December 31, 2019, respectively		1,994			1,710
24,884,251 and 17,100,726 shares issued and outstanding
as of September 30, 2020 and December 31, 2019, respectively								2,488			1,710
Additional paid-in capital		76,454,839			69,409,949			91,881,790			69,409,949
Accumulated deficit		(68,137,527	)		(57,671,052	)		(73,234,057	)		(57,671,052	)

Total Stockholders' Equity		8,319,306			11,740,607			18,650,221			11,740,607

Total Liabilities and Stockholders' Equity	$	11,427,727		$	14,697,619		$	25,847,659		$	14,697,619

The accompanying notes are an integral part of these condensed financial statements.

~~EYENOVIA, INC.~~

~~Condensed Statements of Operations~~

~~(unaudited)~~

For the Three Months Ended For the Six Months Ended
June 30, June 30,
2020 2019 2020 2019

Operating Expenses:
Research and development $ 2,915,250 $ 3,568,022 $ 6,549,537 $ 7,576,918
General and administrative 2,104,163 1,809,106 3,940,945 3,751,869

Total Operating Expenses 5,019,413 5,377,128 10,490,482 11,328,787
Loss From Operations (5,019,413 ) (5,377,128 ) (10,490,482 ) (11,328,787 )

Other Income:
Small Business Administration Economic
Injury Disaster grant 10,000 - 10,000 -
Interest expense (6,351 ) - (10,032 ) -
Interest income 199 43,616 24,039 62,891

Net Loss $ (5,015,565 ) $ (5,333,512 ) $ (10,466,475 ) $ (11,265,896 )

Net Loss Per Share
- Basic and Diluted $ (0.25 ) $ (0.44 ) $ (0.56 ) $ (0.94 )

Weighted Average Number of
Common Shares Outstanding
- Basic and Diluted 19,821,215 12,034,450 18,563,864 11,975,035

EYENOVIA, INC.

~~The accompanying notes are an integral part of these condensed financial statements.~~

EYENOVIA, INC.

Condensed Statements of Changes in Stockholders’ Equity
(unaudited)

For the Six Months Ended June 30, 2020
Additional Total
Common Stock Paid-In Accumulated Stockholders'
Shares Amount Capital Deficit Equity
Balance - January 1, 2020 17,100,726 $ 1,710 $ 69,409,949 $ (57,671,052 ) $ 11,740,607

Issuance of common stock and warrants in public offering [1] 2,675,293 267 5,451,475 - 5,451,742

Stock-based compensation - - 583,865 - 583,865

Net loss - - - (5,450,910 ) (5,450,910 )

Balance - March 31, 2020 19,776,019 1,977 75,445,289 (63,121,962 ) 12,325,304

Exercise of stock warrants 167,664 17 376,404 - 376,421

Stock-based compensation - - 633,146 - 633,146

Net loss - - - (5,015,565 ) (5,015,565 )

Balance - June 30, 2020 19,943,683 $ 1,994 $ 76,454,839 $ (68,137,527 ) $ 8,319,306

~~[1] Includes gross proceeds of $5,984,931, less total issuance costs of $533,189.~~

For the Six Months Ended June 30, 2019
Additional Total
Common Stock Paid-In Accumulated Stockholders'
Shares Amount Capital Deficit Equity
Balance - January 1, 2019 11,468,996 $ 1,147 $ 53,388,216 $ (36,514,294 ) $ 16,875,069

Exercise of stock options on a cashless basis 236,466 24 (24 ) - -

Exercise of stock options 313,686 31 483,857 - 483,888

Stock-based compensation - - 1,032,960 - 1,032,960

Net loss - - - (5,932,384 ) (5,932,384 )

Balance - March 31, 2019 12,019,148 1,202 54,905,009 (42,446,678 ) 12,459,533

Exercise of stock options 34,815 3 67,886 - 67,889

Stock-based compensation - - 424,019 - 424,019

Net loss - - - (5,333,512 ) (5,333,512 )

Balance - June 30, 2019 12,053,963 $ 1,205 $ 55,396,914 $ (47,780,190 ) $ 7,617,929

~~The accompanying notes are an integral part of these condensed financial statements.~~

EYENOVIA, INC.

Condensed Statements of Cash Flows
(unaudited)
For the Six Months Ended
June 30,
2020 2019
Cash Flows From Operating Activities
Net loss $ (10,466,475 ) $ (11,265,896 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 49,343 5,106
Stock-based compensation 1,217,011 1,456,979
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (137,187 ) (436,805 )
Accounts payable (462,658 ) 216,186
Accrued compensation (342,967 ) (474,404 )
Accrued expenses and other current liabilities 227,795 (544,767 )
Security deposit (1,235 ) -
Deferred rent (6 ) 3,233

Net Cash Used In Operating Activities (9,916,379 ) (11,040,368 )

Cash Flows From Investing Activities
Purchases of property and equipment (132,243 ) -

Net Cash Used In Investing Activities (132,243 ) -

Cash Flows From Financing Activities
Proceeds from sale of common stock in private placement [1] 5,569,136 -
Proceeds from exercise of stock warrants 376,421 -
Proceeds from PPP 7(a) Loan 463,353 -
Repayments of notes payable (209,324 ) -
Payment of private placement issuance costs (117,394 ) -
Proceeds from exercise of stock options - 551,777

Net Cash Provided By Financing Activities 6,082,192 551,777

Net Decrease in Cash and Cash Equivalents (3,966,430 ) (10,488,591 )

Cash and cash equivalents - Beginning of Period 14,152,601 19,728,200

Cash and cash equivalents - End of Period $ 10,186,171 $ 9,239,609

Condensed Statements of Operations

~~[1] Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the offering proceeds.~~(unaudited)

Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest expense $ 6,032 $ -
Income taxes $ - $ -

Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchase of insurance premium financed by note payable $ (475,216 ) $ -
Exercise of stock options on a cashless basis $ - $ 24
Deferred offering costs included in accounts payable $ - $ 77,376

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2020			2019			2020			2019
Operating Expenses:
Research and development	$	3,363,759		$	3,201,196		$	9,913,296		$	10,778,114
General and administrative		1,728,366			1,489,739			5,669,311			5,241,608

Total Operating Expenses		5,092,125			4,690,935			15,582,607			16,019,722

Loss From Operations		(5,092,125	)		(4,690,935	)		(15,582,607	)		(16,019,722	)

Other Income (Expense):
Small Business Administration Economic Injury Disaster grant		-			-			10,000			-
Interest expense		(4,945	)		-			(14,977	)		-
Interest income		540			41,557			24,579			104,448

Net Loss	$	(5,096,530	)	$	(4,649,378	)	$	(15,563,005	)	$	(15,915,274	)

Net Loss Per Share - Basic and Diluted	$	(0.23	)	$	(0.29	)	$	(0.79	)	$	(1.19	)

Weighted Average Number of Common Shares Outstanding - Basic and Diluted		22,206,195			16,270,728			19,802,999			13,422,667

The accompanying notes are an integral part of these condensed financial statements.

EYENOVIA, INC.

Condensed Statements of Changes in Stockholders’ Equity

(unaudited)

For the Nine Months Ended September 30, 2020
Additional Total
Common Stock Paid-In Accumulated Stockholders'
Shares Amount Capital Deficit Equity
Balance - January 1, 2020 17,100,726 $ 1,710 $ 69,409,949 $ (57,671,052 ) $ 11,740,607
Issuance of common stock and warrants in private placement [1] 2,675,293 267 5,451,475 - 5,451,742
Stock-based compensation - - 583,865 - 583,865
Net loss - - - (5,450,910 ) (5,450,910 )
Balance - March 31, 2020 19,776,019 1,977 75,445,289 (63,121,962 ) 12,325,304
Exercise of stock warrants 167,664 17 376,404 - 376,421
Stock-based compensation - - 633,146 - 633,146
Net loss - - - (5,015,565 ) (5,015,565 )
Balance - June 30, 2020 19,943,683 1,994 76,454,839 (68,137,527 ) 8,319,306
Issuance of common stock in public offering [2] 3,833,334 383 12,495,325 - 12,495,708
Exercise of stock warrants 1,080,497 108 2,269,562 - 2,269,670
Exercise of stock options 26,737 3 52,134 - 52,137
Stock-based compensation - - 609,930 - 609,930
Net loss - - - (5,096,530 ) (5,096,530 )
Balance - September 30, 2020 24,884,251 $ 2,488 $ 91,881,790 $ (73,234,057 ) $ 18,650,221
[1] Includes gross proceeds of $5,984,931, less total issuance costs of $533,189.
[2] Includes gross proceeds of $13,800,002, less total issuance costs of $1,304,294.
For the Nine Months Ended September 30, 2019
Additional Total
Common Stock Paid-In Accumulated Stockholders'
Shares Amount Capital Deficit Equity
Balance - January 1, 2019 11,468,996 $ 1,147 $ 53,388,216 $ (36,514,294 ) $ 16,875,069
Exercise of stock options on a cashless basis 236,466 24 (24 ) - -
Exercise of stock options 313,686 31 483,857 - 483,888
Stock-based compensation - - 1,032,960 - 1,032,960
Net loss - - - (5,932,384 ) (5,932,384 )
Balance - March 31, 2019 12,019,148 1,202 54,905,009 (42,446,678 ) 12,459,533
Exercise of stock options 34,815 3 67,886 - 67,889
Stock-based compensation - - 424,019 - 424,019
Net loss - - - (5,333,512 ) (5,333,512 )
Balance - June 30, 2019 12,053,963 1,205 55,396,914 (47,780,190 ) 7,617,929
Issuance of common stock in public offering [1] 5,046,763 505 12,958,070 - 12,958,575
Stock-based compensation - - 476,843 - 476,843
Net loss - - - (4,649,378 ) (4,649,378 )
Balance - September 30, 2019 17,100,726 $ 1,710 $ 68,831,827 $ (52,429,568 ) $ 16,403,969
[1] Includes gross proceeds of $14,030,001, less total issuance costs of $1,071,931.
The accompanying notes are an integral part of these condensed financial statements.

EYENOVIA, INC.
Condensed Statements of Cash Flows
(unaudited)
For the Nine Months Ended
September 30,
2020 2019
Cash Flows From Operating Activities
Net loss $ (15,563,005 ) $ (15,915,274 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 71,628 8,494
Stock-based compensation 1,826,941 1,933,822
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (231,194 ) (264,221 )
Deferred license costs (1,600,000 ) -
Accounts payable (76,596 ) 85,745
Accrued compensation (172,318 ) (320,610 )
Accrued expenses and other current liabilities (106,471 ) (430,838 )
Deferred license fee 4,000,000 -
Security deposit (1,235 ) -
Deferred rent (1,119 ) 3,770

Net Cash Used In Operating Activities (11,853,369 ) (14,899,112 )
Cash Flows From Investing Activities
Purchases of property and equipment (202,046 ) (43,478 )
Net Cash Used In Investing Activities (202,046 ) (43,478 )
Cash Flows From Financing Activities
Proceeds from sale of common stock in public offering [1] - 13,214,949
Proceeds from sale of common stock and warrants in private placement [2] 5,569,136 -
Proceeds from sale of common stock in public offering [3] 12,734,002
Proceeds from exercise of stock warrants 2,646,091 -
Proceeds from PPP 7(a) Loan 463,353 -
Repayments of notes payable (368,289 ) -
Payment of public offering issuance costs (329,038 ) (256,374 )
Proceeds from exercise of stock options 52,137 551,777

Net Cash Provided By Financing Activities 20,767,392 13,510,352
Net Increase (Decrease) in Cash and Cash Equivalents 8,711,977 (1,432,238 )
Cash and cash equivalents - Beginning of Period 14,152,601 19,728,200
Cash and cash equivalents - End of Period $ 22,864,578 $ 18,295,962
[1] Includes gross proceeds of $14,030,001, less issuance costs of $815,052 deducted directly from the offering proceeds.
[2] Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the private placement proceeds.
[3] Includes gross proceeds of $13,800,002, less issuance costs of $1,066,000 deducted directly from the offering proceeds.
Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest expense $ 7,961 $ -
Income taxes $ - $ -
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Accrual of public offering costs $ (26,650 ) $ -
Purchase of insurance premium financed by note payable $ (475,216 ) $ -
Exercise of stock options on a cashless basis $ - $ 24
The accompanying notes are an integral part of these condensed financial statements.

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1 – Business Organization, Nature of Operations and Basis of Presentation

Eyenovia. Inc. (“Eyenovia” or the “Company”) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system branded the Optejet^®, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products.

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of ~~June~~September 30, 2020 and for the three and ~~six~~nine months ended ~~June~~September 30, 2020 and 2019. The results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2020 are not necessarily indicative of the operating results for the full year ending December 31, 2020 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2019 and for the year then ended, which were included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020.

Note 2 – Summary of Significant Accounting Policies

Since the date of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

Liquidity ~~and Going Concern~~

As of ~~June~~September 30, 2020, the Company had cash and cash equivalents of approximately ~~$10.2~~$22.9 million and an accumulated deficit of approximately ~~$68.1~~$73.2 million. For the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, the Company incurred net losses of approximately ~~$10.5~~$15.6 million and ~~$11.3~~$15.9 million, respectively, and used cash in operations of approximately ~~$9.9~~$11.9 million and ~~$11.0~~$14.9 million, respectively. Subsequent to ~~June~~September 30, 2020, wethe Company entered into a License Agreement (the “Bausch License Agreement”) with ~~Arctic Vision (Hong Kong) Limited~~a subsidiary of Bausch Health Companies Inc. (“~~Arctic Vision”~~Bausch Health”) pursuant to which wethe Company received an upfront payment from Bausch Health of $4.0 million before any payments to Senju Pharmaceutical Co., Ltd. (“Senju”). In addition, we received approximately $1.3 million from the exercise of warrants issued in our private placement of common stock and warrants that closed on March 24, 2020.$10.0 million. See Note 11 – Subsequent Events for details.

The Company ~~has not yet generated revenues or achieved profitability~~believes its current cash on hand, including the proceeds received from the Bausch License Agreement and ~~expects~~warrant exercises, is sufficient to ~~continue to incur cash outflows~~meet its operating and capital requirements for at least the next twelve months from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date ~~that~~ these financial statements are issued. ~~Implementation of~~Thereafter, the ~~Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability~~Company may need to raise further capital, through the sale of additional equity or debt securities, ~~or otherwise,~~ to support its future operations.
The Company’s operating needs include the planned costs to operate its business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully manufacture its products and commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

EYENOVIA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Note 2 – Summary of Significant Accounting Policies – Continued

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.

The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of ~~June~~September 30, 2020 and December 31, 2019, the Company had cash balances in excess of FDIC insurance limits of ~~$9,936,171~~$22,614,578 and $13,902,601, respectively.

~~Stock-Based Compensation~~
The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.
~~Convertible~~Derivative Instruments

The Company evaluates its ~~convertible~~embedded conversion options and any freestanding instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record ~~embedded conversion options and any related freestanding instruments~~them at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. ~~Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.~~
If the instrument is determined to not be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the commitment date fair value to the effective conversion price of the instrument.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:

June 30, September 30,
2020 2019 2020 2019
Options 3,290,357 1,563,366 3,410,540 2,237,438
Warrants 3,344,154 - 2,095,993 -
Restricted stock units 60,355 20,165 43,728 60,355
Total potentially dilutive shares 6,694,866 1,583,531 5,550,261 2,297,793

EYENOVIA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Note 2 – Summary of Significant Accounting Policies – Continued

Recently Adopted Accounting Pronouncements

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard, ~~was~~which the Company adopted on January 1, 2020, ~~and~~ did not have a material impact on the Company’s financial position, results of operations or cash flows.
In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company adopted ASU 2020-03 upon issuance, which did not have a material impact on the Company’s unaudited condensed financial statements.

Note 3 – Prepaid Expenses and Other Current Assets

As of ~~June~~September 30, 2020 and December 31, 2019, prepaid expenses and other current assets consisted of the following:

June 30, December 31, September 30, December 31,
2020 2019 2020 2019
(unaudited) (unaudited)
Prepaid insurance expenses $ 433,639 $ 33,923 $ 271,866 $ 33,923
Payroll tax receivable 176,385 95,233 179,260 95,233
Prepaid Nasdaq annual fees 65,420 -
Arctic Vision expense reimbursement receivable 149,675 -
Prepaid research and development expenses 26,660 17,978 74,540 17,978
Prepaid patent expenses 35,916 12,404
Prepaid Board of Director fees 68,250 -
Prepaid subscription fees 46,007 10,600
Prepaid conference expenses 35,003 10,600 36,529 2,463
Prepaid rent and security deposit 21,994 2,463 31,945 -
Prepaid patent expenses 29,499 12,404
Other 14,066 24,079 15,519 24,079
Total prepaid expenses and other current assets $ 809,083 $ 196,680 $ 903,090 $ 196,680

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

Note 4 – Accrued Compensation

As of ~~June~~September 30, 2020 and December 31, 2019, accrued compensation consisted of the following:

June 30, December 31,
2020 2019
(unaudited)
Accrued bonus expenses $ 380,320 $ 897,839
Accrued payroll expenses 193,586 19,034
Total accrued compensation $ 573,906 $ 916,873

~~EYENOVIA, INC.~~
~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~
~~(UNAUDITED)~~
September 30, December 31,
2020 2019
(unaudited)
Accrued bonus expenses $ 579,604 $ 897,839
Accrued payroll expenses 164,951 19,034
Total accrued compensation $ 744,555 $ 916,873

Note 5 – Accrued Expenses and Other Current Liabilities

As of ~~June~~September 30, 2020 and December 31, 2019, accrued expenses and other current liabilities consisted of the following:

June 30, December 31, September 30, December 31,
2020 2019 2020 2019
(unaudited) (unaudited)
Accrued research and development expenses $ 294,421 $ 208,175
Accrued public offering costs 14,102 -
Accrued professional services 11,000 97,396
Accrued legal expenses $ 409,074 $ - 14,195 -
Accrued research and development expenses 201,794 208,175
Accrued professional services 44,368 97,396
Accrued franchise tax 4,980 40,995
Credit card payable 19,887 56,979 3,507 56,979
Leasehold improvements - 42,500 - 42,500
Accrued franchise tax - 40,995
Accrued travel and entertainment expenses 5,730 7,385 1,273 7,385
Other 372 - 30,131 -
Total accrued expenses and other current liabilities $ 681,225 $ 453,430 $ 373,609 $ 453,430

Note 6 – Notes Payable

As of ~~June~~September 30, 2020 and December 31, 2019, notes payable consisted of the following:

September 30, 2020 December 31, 2019
June 30, December 31, (unaudited)
2020 2019 Current Non-Current Current Non-Current
(unaudited) Portion Portion Total Portion Portion Total
Paycheck Protection Program loan $ 463,353 $ - $ 39,015 $ 424,338 $ 463,353 $ - $ - $ -
Directors and officers insurance policy loan 265,892 - 106,927 - 106,927 - - -
729,245 -
Less current maturities (421,599 ) -
$ 307,646 $ -
Total $ 145,942 $ 424,338 $ 570,280 $ - $ - $ -

On February 24, 2020, the Company issued a note payable (the “Note”) for the purchase of a ~~directors~~directors’ and ~~officers~~officers’ liability insurance policy. The Note is payable in 9nine monthly payments of $53,750 for an aggregate principal amount of $475,216. The Note accrues interest at a rate of 4.29% per year and matures on November 24, 2020. During the ~~six~~nine months ended ~~June~~September 30, 2020, the Company repaid principal on the Note in the aggregate amount of ~~$209,324.~~$368,289.

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 6 – Notes Payable – Continued

On May 8, 2020, the Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the “PPP Loan”). The PPP Loan ~~matures~~provides for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, ~~and~~the maturity date. The PPP Loan bears interest at a fixed rate of 1.00% per annum.

~~EYENOVIA, INC.~~
~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~
~~(UNAUDITED)~~
~~Note 6 – Notes Payable – Continued~~

Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company is eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for certain permissible purposes as set forth in the PPP Loan, including, but not limited to, payroll costs and mortgage interest, rent or utility costs (collectively, “Qualifying Expenses”) incurred during the 24 weeks subsequent to funding, and on the maintenance of employee and compensation levels following the funding of the PPP Loan. The Company intends to use the proceeds of its PPP Loan for Qualifying Expenses. However, no assurance is provided that the Company will be able to obtain forgiveness of its PPP Loan in whole or in part. Any amounts that are not forgiven incur interest at 1.0% per annum and monthly repayments of principal and interest are deferred until six months after the Small Business Administration makes a determination on forgiveness. While the PPP Loan currently has a two-year maturity, the amended law permits the borrower to request a five-year maturity from its lender.

During the three months ended ~~June~~September 30, 2020 and 2019, the Company recorded interest expense of ~~$4,333~~$3,824 and $0, respectively, and ~~$6,032~~$9,855 and $0 for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, ~~respectively.~~respectively.

Note 7 – Commitments and Contingencies
See Note 8 – Related Party Transactions for certain commitments and contingencies entered into with certain related parties.

Litigations, Claims and Assessments

The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.
Arctic Vision License Agreement
On August 10, 2020, the Company entered into a License Agreement (the “Arctic Vision License Agreement”) with Arctic Vision (Hong Kong) Limited (“Arctic Vision”) pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.
Under the terms of the Arctic Vision License Agreement, the Company received an upfront payment of $4.0 million, before any payments to Senju Pharmaceutical Co., Ltd. (“Senju”). The Company will record this payment as a deferred license fee in the unaudited condensed balance sheet until the payment is earned. The Company will consider payment earned once certain trial data has been submitted to Arctic Vision, permitting Arctic Vision to obtain regulatory approval with the National Medical Products Administration. In addition, the Company may receive up to a total of $41.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. Arctic Vision also will purchase its supply of MicroPine and MicroLine from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to its Exclusive License Agreement with Senju, as amended. See Note 8 – Related Party Transactions. During the three and nine months ended September 30, 2020, the Company did not earn any fees related to the Arctic Vision License Agreement.

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

Note 8 – Related Party Transactions

Consulting Agreements

A company in which a member of the Company’s Board of Directors is part owner iswas a party to a consulting agreement with the Company, dated July 6, 2017, ~~that provides~~which provided for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The consulting agreement was terminated on September 1, 2020. The director remains on the Board. The Company incurred expenses of ~~$28,701~~$19,134 and ~~$50,634~~$49,451 for the three months ended ~~June~~September 30, 2020 and 2019, respectively, and $57,402 and ~~$98,835~~$151,853 for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, respectively, related to the agreement which was included within general and administrative expenses on the unaudited condensed statements of operations.

Lease Agreements

The Company’s Vice President of Research and Development and Manufacturing (“VP of R&D”) owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September 15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and security deposit to $4,012. The lease agreement was amended again on April 6, 2020 to lease additional space and increase the monthly base rent and security deposit to $5,247. On September 15, 2020, the Company agreed to extend the lease term until September 14, 2022 and increase the monthly base rent and security deposit to $5,404. The Company made $70,000 of leasehold improvements related to this lease which are included on the balance sheet. The Company’s rent expense amounted to ~~$15,494~~$15,982 and $12,036 for the three months ended ~~June~~September 30, 2020 and 2019, respectively, and ~~$27,530~~$43,512 and ~~$24,072, respectively,~~$36,108 for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, respectively.
Research and Development Activities
The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the three and nine months ended September 30, 2020, the Company recognized research and development expense of $323,187 and $795,992, respectively, related to services provided by such vendor. During the three and nine months ended September 30, 2019, the Company recognized research and development expense of $197,543 and $728,103, respectively, related to services provided by such vendor. The Company had a liability of $120,584 and $89,052 to the vendor as of September 30, 2020 and December 31, 2019, respectively.
The Company recognized $46,050 and $143,437 of compensation expense related to the VP of R&D’s salary during the three and nine months ended September 30, 2020, respectively. The Company recognized $46,010 and $140,110 of compensation expense related to the VP of R&D’s salary during the three and nine months ended September 30, 2019, respectively.
License Agreement
On March 8, 2015, the Company entered into an Exclusive License Agreement (the “Exclusive License Agreement”) with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license, with rights of sublicense, for its medical device technology for the piezoelectric delivery of ophthalmic medications to develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute such products in Asia. In consideration for the license, Senju agreed to pay to Eyenovia 5% royalties on sales (net of certain manufacturing costs) for the term of the Exclusive License Agreement, subject to certain adjustments upon the loss of patent coverage. The Exclusive License Agreement will continue in full force and effect, on a country-by-country basis, until the later to occur of: (i) the tenth (10th) anniversary of the first commercial sale of such a product candidate in a country or (ii) the expiration of the licensed patents in a country. As of the date of this filing, there had been no commercial sales of such a product in Asia, and, therefore, no royalties had been earned. Senju is owned by the family of a former member of the Company’s Board of Directors and, together, they beneficially own greater than 5% of the Company’s common stock.

EYENOVIA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Note 8 – Related Party Transactions - Continued

~~Research and Development Activities~~
The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the three and six months ended June 30, 2020, the Company recognized research and development expense of $229,034 and $472,805, respectively, related to services provided by such vendor. During the three and six months ended June 30, 2019, the Company recognized research and development expense of $210,420 and $530,560, respectively, related to services provided by such vendor. The Company had a liability of $95,087 and $89,052 to the vendor as of June 30, 2020 and December 31, 2019, respectively.
The Company recognized $46,050 and $97,387 of compensation expense related to the VP of R&D’s salary during the three and six months ended June 30, 2020, respectively. The Company recognized $46,050 and $94,100 of compensation expense during the three and six months ended June 30, 2019, respectively.
~~License Agreement~~
~~On March 8, 2015, the Company entered into an Exclusive~~ License Agreement (the “Exclusive License Agreement”) with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license, with rights of sublicense, for its medical device technology for the piezoelectric delivery of ophthalmic medications to develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute such products in Asia. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties on sales (net of certain manufacturing costs) for the term of the Exclusive License Agreement, subject to certain adjustments upon the loss of patent coverage. The Exclusive License Agreement will continue in full force and effect, on a country-by-country basis, until the later to occur of: (i) the tenth (10th) anniversary of the first commercial sale of such a product candidate in a country or (ii) the expiration of the licensed patents in a country. As of the date of this filing, there had been no commercial sales of such a product in Asia, and, therefore, no royalties had been earned. Senju is owned by the family of a former member of the Company’s Board of Directors and, together, they beneficially own greater than 5% of the Company’s common stock.– Continued

On April 8, 2020, Eyenovia entered into an amendment (the “License Amendment”) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the ~~“Licensed~~“Senju Licensed Products”) previously licensed to Senju in China (including the People’s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the “Territory”) if such a license is executed by the Company by April 8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.

Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Unless a third-party license is executed by the Company prior to April 8, 2021 (in which case, subject to early termination the License Amendment shall remain in effect for the duration of such license), the License Amendment terminates on April 8, 2021, but may be terminated earlier by Senju upon the Company’s material breach of the License Amendment, subject to a 60-day cure period.

The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the “Letter Agreement”). Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. During the nine months ended September 30, 2020, the Company paid Senju $1.6 million in connection with the Arctic Vision License Agreement which was recorded as deferred license costs in the Company’s unaudited condensed balance sheet and will be recognized as expense upon earning the related fee. See Note 117 – ~~Subsequent Events~~Commitments and Contingencies for additional details.

~~EYENOVIA, INC.~~
~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~
~~(UNAUDITED)~~

Note 9 – Stockholders’ Equity

Equity Incentive Plan

On April 7, 2020, the Company’s Board of Directors approved the Company’s Amended and Restated 2018 Omnibus Stock Incentive Plan (the “Restated Plan”), which stockholders approved on June 30, 2020. The Restated Plan makes certain changes to the Company’s 2018 Omnibus Stock Incentive Plan, as amended (the “2018 Plan”). For example, the Restated Plan increases the number of shares of Company’s common stock reserved for issuance under the 2018 Plan to 2,950,000 shares. The Restated Plan requires that all equity awards issued under the Restated Plan vest at least twelve months from the applicable grant date, subject to accelerated vesting, and provides that no dividend or dividend equivalent will be paid on any unvested equity award, although dividends with respect to unvested portions of equity may accrue and be paid when, and if, the awards later vest and the shares are actually issued to the grantee. In addition, the Restated Plan sets an annual limit on the grant date fair value of awards to any non-employee director, together with any cash fees paid during the year, of $150,000, subject to certain exceptions for a non-executive chair of the Board. Finally, the Restated Plan makes several administrative changes to the 2018 Plan, including to clarify that awards made under the Restated Plan are intended to be exempt from or comply with Section 409(A) of the Internal Revenue Code of 1986, as amended.

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity – Continued
Securities Purchase Agreement

On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company’s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (“Class A Warrant”), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (“Class B Warrant”) (collectively, the Class A Warrants and Class B Warrants, the “Warrants”). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.45 million of net proceeds in the offering after deducting placement agent fees and offering expenses of $0.53 million. In the offering, the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share. ~~These Warrants, taken together, had an intrinsic value of $1,012,815 as of June 30, 2020.~~ The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share. ~~These Warrants, taken together, had an intrinsic value of $659,930 at June 30, 2020.~~See “Warrants” below for additional details.

In connection with the ~~offering,~~private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13, 2020.
Warrants
A summary of the Warrant activity during the nine months ended September 30, 2020 is presented below:
Weighted
Weighted Average
Average Remaining Aggregate
Number of Exercise Life Intrinsic
Warrants Price In Years Value
Outstanding January 1, 2020 - $ -
Granted 3,344,154 2.33
Exercised (1,248,161 ) 2.19
Outstanding September 30, 2020 2,095,993 $ 2.41 4.0 $ 1,391,817

Exercisable September 30, 2020 2,095,993 $ 2.41 4.0 $ 1,391,817

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity – Continued
Warrants – Continued
The following table presents information related to Warrants as of September 30, 2020:
Warrants Outstanding Warants Exercisable
Weighted
Outstanding Average Exercisable
Exercise Number of Remaining Life Number of
Price Warrants In Years Warrants
$2.0580 133,229 0.5 133,229
$2.2700 144,256 0.5 144,256
$2.4696 1,602,128 4.5 1,602,128
$2.7240 216,380 4.5 216,380
2,095,993 4.0 2,095,993
During the three months ended September 30, 2020, Warrants for the purchase of 1,080,497 shares of the Company’s common stock with exercise prices of either $2.058 or $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $2.3 million. During the nine months ended September 30, 2020, Warrants for the purchase of 1,248,161 shares of the Company’s common stock with exercise prices of either $2.058 or $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $2.6 million.
Underwritten Public Offering
On August 19, 2020, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with several underwriters (the “Underwriters”) in connection with the public offering (the “Offering”) of 3,333,334 shares of the Company’s common stock at a price of $3.60 per share, less underwriting discounts and commissions. In addition, pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 500,000 shares of the Company’s common stock at the same price. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification by the ~~SEC~~Company and the Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities.
The closing of the Offering occurred on ~~May 13,~~August 21, 2020. At closing, the Company issued 3,833,334 shares of common stock and received net proceeds of approximately $12.5 million after deducting underwriting discounts and commissions and offering expenses of approximately $1.3 million.
The Offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-229365), including the prospectus dated February 12, 2019, as supplemented by the prospectus supplement dated August 19, 2020.

Stock Options

On January 31, 2020, the Company granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $89,400, which the Company expects to recognize over the vesting period.

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity – Continued
Stock Options - Continued
On May 28, 2020, the Company granted ten-year stock options to purchase 263,500 shares of common stock to its employees under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.89 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $587,100, which the Company expects to recognize over the vesting period.

~~EYENOVIA, INC.~~
~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~
~~(UNAUDITED)~~
~~Note 9 – Stockholders’ Equity – Continued~~
~~Stock Options - Continued~~
On June 3, 2020, the Company granted ten-year stock options to purchase 764,419 shares of common stock to its executive ~~directors~~officers under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $2.72 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $1,603,600, which the Company expects to recognize over the vesting period.

On July 28, 2020, the Company granted ten-year stock options to purchase 43,000 shares of common stock to an employee under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.71 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $122,400, which the Company expects to recognize over the vesting period.
On September 8, 2020, the Company granted ten-year stock options to purchase 45,000 shares of common stock to employees and consultants under the Restated Plan. The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $3.48 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $126,700, which the Company expects to recognize over the vesting period.
On September 11, 2020, the Company granted ten-year stock options to purchase 58,920 shares of common stock under the Restated Plan to members of its Board of Directors. The shares vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The stock options have an exercise price of $3.43 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date fair value of $155,400, which the Company expects to recognize over the vesting period.
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

For the Three Months Ended For the Six Months Ended For the Three Months Ended For the Nine Months Ended
June 30, June 30, September 30, September 30,
2020 2019 2020 2019 2020 2019 2020 2019
Expected term (years) 5.85 n/a 5.85 5.85 5.85 - 10.00 5.85 - 10.00 5.85 - 10.00 5.85 - 10.00
Risk free interest rate 0.34% - 0.38% n/a 0.34% - 1.32% 2.53% 0.26% - 0.69% 1.42% - 1.55% 0.26% - 1.32% 1.42% - 2.53%
Expected volatility 99% n/a 96% - 99% 139% 98% - 99% 134% 96% - 99% 134% - 139%
Expected dividends 0.00% n/a 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not have a trading history to support its historical volatility calculations. Accordingly, the Company used a blended volatility whereby it uses its historical volatility for the period from its IPO through the valuation date and uses the average of peer-group data of six comparable entities to supplement its own historical data for the preceding years in computing its expected volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

EYENOVIA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 9 – Stockholders’ Equity – Continued
Stock Options – Continued
The weighted average estimated grant date fair value of the stock options granted for the three months ended ~~June~~September 30, 2020 and 2019 was approximately ~~$2.13~~$2.71 and $3.11 per ~~share. There were no stock options granted during the three months ended June 30, 2019.~~share, respectively. The weighted average estimated grant date fair value of the stock options granted for the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019 was approximately ~~$2.17~~$2.24 and ~~$2.50~~$3.10 per share, respectively.

A summary of the stock option activity during the ~~six~~nine months ended ~~June~~September 30, 2020 is presented below:

Weighted Weighted
Weighted Average Weighted Average
Average Remaining Aggregate Average Remaining Aggregate
Number of Exercise Life Intrinsic Number of Exercise Life Intrinsic
Options Price In Years Value Options Price In Years Value
Outstanding January 1, 2020 2,237,438 $ 3.51 2,237,438 $ 3.51
Granted 1,052,919 2.81 1,199,839 2.90
Exercised - - (26,737 ) 1.95
Outstanding June 30, 2020 3,290,357 $ 3.29 8.3 $ 1,131,580
Outstanding September 30, 2020 3,410,540 $ 3.31 8.2 $ 1,652,315

Exercisable June 30, 2020 1,436,735 $ 3.38 6.9 $ 1,019,817
Exercisable September 30, 2020 1,698,779 $ 3.43 7.0 $ 1,280,864
The following table presents information related to stock options as of September 30, 2020:
Options Outstanding Options Exercisable
Weighted
Outstanding Average Exercisable
Exercise Number of Remaining Life Number of
Price Options In Years Options
$1.24 260,000 4.5 260,000
$1.95 673,544 6.8 673,544
$2.72 764,419 - -
$2.74 6,000 8.3 3,333
$2.89 263,500 - -
$3.11 681,572 8.9 275,064
$3.43 58,920 - -
$3.48 45,000 - -
$3.71 43,000 - -
$4.00 2,000 8.1 1,223
$4.68 25,000 - -
$5.10 6,000 7.9 4,000
$5.19 16,500 7.9 11,000
$5.25 26,668 6.0 26,501
$6.20 311,499 7.8 265,680
$6.30 60,000 7.8 43,333
$8.72 166,918 7.5 135,101
3,410,540 7.0 1,698,779

EYENOVIA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Note 9 – Stockholders’ Equity -– Continued

Stock ~~Options – Continued~~Option Exercises

~~The following table presents information related to~~During the three and nine months ended September 30, 2020, stock options asfor the purchase of ~~June 30, 2020:~~26,737 shares of the Company’s common stock with an exercise price of $1.95 per share was exercised for proceeds of $52,137.

Options Outstanding Options Exercisable
Weighted
Outstanding Average Exercisable
Exercise Number of Remaining Life Number of
Price Options In Years Options
$ 1.24 260,000 4.7 260,000
$ 1.95 700,281 7.0 678,127
$ 2.72 764,419 - -
$ 2.74 6,000 8.5 2,833
$ 2.89 263,500 - -
$ 3.11 681,572 9.1 45,285
$ 4.00 2,000 8.4 1,056
$ 4.68 25,000 - -
$ 5.10 6,000 8.2 3,500
$ 5.19 16,500 8.2 9,625
$ 5.25 26,668 6.3 24,582
$ 6.20 311,499 8.1 251,933
$ 6.30 60,000 8.0 38,333
$ 8.72 166,918 7.8 121,461
3,290,357 6.9 1,436,735
Restricted Stock Units
On September 11, 2020, the Company granted members of its Board of Directors an aggregate of 43,728 restricted stock units (“RSUs”) under the Restated Plan. Each RSU is subject to settlement into one share of the Company’s common stock. The RSUs vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $150,000, which will be recognized over the vesting period.

Stock-Based Compensation Expense

The Company recorded stock-based compensation expense related to stock options and ~~restricted stock units.~~RSUs. During the three months ended ~~June~~September 30, 2020 and 2019, the Company recorded expense of ~~$633,146~~$609,930 ($~~348,447~~346,293 of which was included within research and development expenses and ~~$284,699~~$263,637 of which was included within general and administrative expenses on the condensed statement of operations) and ~~$424,019~~$476,843 ($~~206,834~~255,323 of which was included within research and development expenses and ~~$217,185~~$221,520 of which was included within general and administrative expenses on the condensed ~~statements~~statement of operations), respectively. During the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, the Company recorded expense of ~~$1,217,011~~$1,826,941 ($~~655,856~~1,002,149 of which was included within research and development expenses and ~~$561,155~~$824,792 was included within general and administrative expenses on the condensed ~~statements~~statement of operations) and ~~$1,456,979~~$1,933,822 ($~~900,917~~1,156,241 of which was included within research and development expenses and ~~$556,062~~$777,581 was included within general and administrative expenses on the condensed ~~statements~~statement of operations) ~~during the six months ended June 30, 2020 and 2019,~~, respectively. As of ~~June~~September 30, 2020, there was ~~$4,312,311~~$4,145,595 of unrecognized stock-based compensation expense which the Company expects to recognize over a weighted average period of ~~2.3~~2.1 years.
~~Warrant Exercises~~
During the three and six months ended June 30, 2020, Warrants to purchase 91,453 and 76,211 shares of common stock with an exercise price of $2.058 and $2.4696 per share, respectively, were exercised for aggregate proceeds of $376,421.

~~EYENOVIA, INC.~~
~~NOTES TO CONDENSED FINANCIAL STATEMENTS~~
~~(UNAUDITED)~~

Note 10 – Employee Benefit Plans

401(k) Plan

In April 2019, the Company adopted the Eyenovia 401(k) Plan (the “Plan”), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2020, the Company’s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the ~~six~~three months ended ~~June~~September 30, 2020 and 2019, the Company recorded expense of ~~$80,486~~$25,535 and ~~$16,043~~$26,989 associated with its matching contributions, respectively. During the ~~three~~nine months ended ~~June~~September 30, 2020 and 2019, the Company recorded expense of ~~$22,515~~$106,021 and $0$43,032 associated with its matching contributions, respectively.

Note 11 – Subsequent Events

~~Warrant Exercises~~
Subsequent to June 30, 2020, Warrants to purchase 497,908 and 94,840 shares of common stock with an exercise price of $2.058 and $2.4696 per share, respectively, were exercised for aggregate proceeds of approximately $1.3 million.
Bausch License ~~Agreements~~Agreement

On ~~August 10,~~October 9, 2020, ~~Eyenovia~~the Company entered into athe Bausch License Agreement ~~(the “License Agreement”) with Arctic Vision~~ pursuant to which ~~Arctic Vision~~Bausch Health may develop and commercialize the Company’s MicroPine ~~for~~therapeutic candidate (the “Bausch Licensed Product”) in the ~~treatment progressive myopia~~United States and ~~MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.~~Canada (the “Licensed Territory”).

EYENOVIA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
Note 11 – Subsequent Events – Continued
Bausch Health License Agreement - Continued
In connection with the Bausch License Agreement, Bausch Health paid the Company an upfront payment of $10.0 million. Bausch Health might also pay the Company up to an aggregate of approximately $35.0 million in additional payments, depending on the achievement of certain regulatory and launch-based milestones. Under the terms of the Bausch License Agreement, ~~Eyenovia received an upfront payment of $4.0 million before any payments to Senju. In addition, Eyenovia may receive up to~~on a ~~total of $41.75 million in additional payments, based~~country-to-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company a royalties on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. Arctic Vision also will purchase its supply of MicroPine and MicroLinea tiered basis (ranging from ~~Eyenovia or, for such products not supplied by Eyenovia, pay Eyenovia a~~ mid-single digit ~~percentage royalty~~to mid-teen percentages) on ~~net~~gross profits from the sales of ~~such products,~~the Bausch Licensed Product in the United States and Canada, subject to certain ~~adjustments. Eyenovia will pay~~adjustments in the event of generic entry, negative gross profits or patent expiration, for a ~~mid-double digit percentage~~period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such ~~payments, royalties,~~country in the Licensed Territory or ~~net proceeds~~the expiration of the last valid patent claim for a Bausch Licensed Product in such ~~supply to Senju pursuant~~country in the Licensed Territory. Under the terms of the Bausch License Agreement, Bausch Health also has assumed oversight and costs related to the ~~Exclusive~~ongoing MicroPine study (the CHAPERONE study).
Bausch Health may terminate the Bausch License Agreement, with ~~Senju, as amended by~~respect to the Bausch Licensed Product to either country in the Licensed Territory, at any time for convenience upon 90 days’ written notice. Both parties have the right to terminate the Bausch License ~~Amendment dated April 8, 2020, and~~Agreement in the event of (i) an uncured material breach after a ~~Letter Agreement dated August 10, 2020.~~
60-day period or (ii) a bankruptcy event.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of the results of operations and financial condition of Eyenovia, Inc. (“Eyenovia,” the “Company,” “we,” “us” and “our”) as of ~~June~~September 30, 2020 and for the three and ~~six~~nine months ended ~~June~~September 30, 2020 and 2019 should be read in conjunction with our unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (“SEC”) on March 30, 2020.

Forward Looking Statements

This report contains “forward-looking statements.” Specifically, all statements other than statements of historical facts included in this report, including regarding our financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “might,” “will,” “continue” “intend,” and “plan” and words or phrases of similar import are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors that could cause actual results and the timing of events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors” included in our most recent Annual report on Form 10-K filed with the SEC. Furthermore, such forward-looking statements speak only as of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print ~~(MAP)~~(MAP™) therapeutics. ~~Eyenovia aims~~We aim to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using ~~its~~our high-precision targeted ocular delivery system, branded the ~~Optejet,~~Optejet®, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than traditional eye drops (~ 90% vs. ~ 50%). ~~Eyenovia’s~~Our technology also can deliver up to a 75% reduction in ocular drug and preservative exposure and has demonstrated significant improvement in the therapeutic index in drugs used for mydriasis and IOP lowering through three Phase II and Phase III trials. Using the Optejet, ~~Eyenovia is~~we are developing the next generation of smart ophthalmic therapeutics which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration, or the FDA. ~~Eyenovia’s~~Our microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. ~~Its~~Our products are classified by the FDA as drugs, and not medical devices or drug-device combination products. Our pipeline is currently focused on the late-stage development of microdosed medications for progressive myopia, presbyopia, and mydriasis.
MicroPine is our first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. In the United States, myopia is estimated to affect approximately 25 million children, with up to 3 million considered to be at risk for high myopia. In February 2019, the FDA accepted our investigational new drug application, or IND, to initiate a Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. We enrolled the first patient in the CHAPERONE study in June 2019. Due to the COVID-19 pandemic, we previously experienced delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites. However, we have since been able to resume enrollment in the CHAPERONE study.

On October ~~29, 2019,~~9, 2020, we entered into a License Agreement (the “Bausch License Agreement”) with a subsidiary of Bausch Health Companies Inc. (“Bausch Health”), pursuant to which Bausch Health may develop and commercialize MicroPine in the ~~Company announced that it~~United States and Canada . Under the terms of the Bausch License Agreement, we received an upfront payment of $10.0 million and we may receive up to a total of $35.0 million in additional payments, based on the achievement of certain regulatory and launch-based milestones. Bausch Health also will pay us royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from sales of MicroPine in the United States and Canada, subject to certain adjustments. Under the terms of the Bausch License Agreement, Bausch Health has assumed oversight and costs related to the ongoing CHAPERONE study.

MicroLine is ~~advancing the development of its MicroLine program~~our pharmacologic treatment for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its MicroPine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication) programs.
presbyopia. Presbyopia is a non-preventable, age-related hardening of the lens, which causes the gradual loss of the eye’s ability to focus on nearby objects. There currently are no known FDA-approved drugs for the improvement of near vision in patients with presbyopia, although other companies have related therapies in their pipeline. ~~Eyenovia has~~We have two planned ~~two~~ Phase III VISION trials for ~~MicroLine. MicroPine is the Company’s first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation~~MicroLine, and sclero-retinal stretching affecting approximately five million people in the United States. In February 2019, the FDA accepted Eyenovia’s investigational new drug application, or IND, to initiate its Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. Eyenovia enrolled its first patient in the CHAPERONE study in June 2019. Due to the COVID-19 pandemic, the Company has previously experienced delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites. However, the Company has since been able to resume enrollment in the CHAPERONE study, and in the coming months, subject to any impacts of the COVID-19 pandemic, ~~anticipates~~we anticipate initiating ~~its~~our Phase III VISION trials ~~for MicroLine. In addition, on~~in 2020.
On August 10, 2020, ~~the Company~~we entered into a License Agreement (the “Arctic Vision License Agreement”) with Arctic Vision (Hong Kong) Limited (“Arctic Vision”), pursuant to which Arctic Vision may develop and commercialize MicroPine ~~for the treatment progressive myopia~~ and MicroLine ~~for the treatment of presbyopia~~ in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. Under the terms of the Arctic Vision License Agreement, we received an upfront payment of $4.0 million before any payments to Senju Pharmaceutical Co., Ltd. (“Senju”). In addition, we may receive up to a total of $41.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. Arctic Vision also will purchase its supply of MicroPine and MicroLine from us or, for such products not supplied by us, pay us a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. We will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Exclusive License Agreement with Senju dated March 8, 2015, as amended by the License Amendment dated April 8, 2020, and a Letter Agreement dated August 10, 2020.

MicroStat (or Mydcombi™) is ~~Eyenovia’s~~our fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States. ~~Eyenovia has~~We have completed ~~its~~two Phase III trials for MicroStat and announced positive results from these studies, known as MIST-1 and MIST-2. ~~The Company~~We currently ~~remains~~remain on track to file a new drug application, or NDA, with the FDA for MicroStat in ~~2020, although the COVID-19 pandemic could change that.~~

Results from our previous three Phase II clinical trials have been published in peer-reviewed literature. Two studies evaluating our mydriatic agents demonstrated how the Optejet consistently delivered precision dosing at the volume of the eye’s natural tear film capacity of 6-8 µL, which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects. In the third study, we evaluated usability, patient tolerability and IOP lowering of microdosed latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved IOP reduction consistent with published literature on latanoprost eye drops, and administration of the medication was successful in a single attempt in more than 90% of cases. Based on the results from these clinical trials, we are advancing MicroLine, MicroPine, MicroStat, and MicroProst (should we resume the program) utilizing the 505(b)(2) pathway. Where possible, we also intend to use this pathway for future clinical trials in new indications with significant unmet needs.2020.

We have not completed development of any product candidate and we have therefore not generated any revenues from product sales.

Historically, we have financed our operations principally through equity offerings, including our initial public offering, numerous ~~follow-on~~ public offerings in 2018, 2019 and ~~2019,~~August 2020, and our private placement that closed in March 2020. Recently we also have generated cash through licensing arrangements. Based upon our current operating plan, ~~there is substantial doubt about~~we believe we will have sufficient cash to meet our ~~ability to continue as a going concern~~projected operating requirements for ~~a period of~~ at least the next twelve ~~months. Our ability to continue as a going concern depends on our ability~~months from the date of filing. Thereafter, we may need to raise ~~additional~~further capital, through the sale of additional equity or debt securities, to support our future operations. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs.

Our net losses were ~~$5.0~~$5.1 million and ~~$10.5~~$15.6 million for the three and ~~six~~nine months ended ~~June~~September 30, 2020. As of ~~June~~September 30, 2020, we had working capital and an accumulated deficit of ~~$8.2~~$18.6 million and ~~$68.1~~$73.2 million, respectively.

Financial Overview

Revenue

We have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. Our ability to generate revenues will depend heavily on the successful development, regulatory approval and commercialization of our micro-therapeutic product candidates.

Recently, we have licensed the use of our products in certain regions and expect to begin to earn fees from upfront payments and additional payments based on various development and regulatory milestones.
Research and Development Expenses

Research and development expenses are incurred in connection with the research and development of our microdose-therapeutics and consist primarily of contract service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:

· direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;

· personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and

· facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities.

We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.

We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.

General and Administrative Expenses

General and administrative expenses ~~consist~~for the nine months ended September 30, 2020 totaled $5.7 million, an increase of $0.5 million, or 8%, as compared to $5.2 million recorded for the nine months ended September 30, 2019. This increase was primarily ~~of payroll and~~attributable to a $0.4 million increase in professional services related to business development activities, a $0.3 million in patent related expenses ~~legal~~which is expected to continue to increase as programs are further developed and ~~other professional services, as well as non-cash stock-based compensation expense. We anticipate that our general and administrative expenses will~~a $0.1 million increase in liability insurance related to an increase in the ~~future as we increase our headcount to support our continued research~~insurance premium on directors and ~~development~~officers insurance. This was offset by a $0.3 million decrease in travel and ~~the potential commercialization of our product candidates. We also anticipate increased~~entertainment expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with being a public company are expected to continue increasing.the impact of the COVID-19 pandemic.

Results of Operations

Three Months Ended ~~June~~September 30, 2020 Compared with Three Months Ended ~~June~~September 30, 2019

Research and Development Expenses

Research and development expenses for the three months ended ~~June~~September 30, 2020 totaled ~~$2.9~~$3.4 million, ~~a decrease~~an increase of ~~$0.7~~$0.2 million, or ~~18%~~5%, as compared to ~~$3.6~~$3.2 million recorded for the three months ended, ~~June~~September 30, 2019. Research and development expenses consisted of the following:

For the Three Months Ended For the Three Months Ended
June 30, September 30,
2020 2019 2020 2019
Direct clinical and non-clinical expenses $ 1,503,565 $ 2,219,648 $ 1,745,880 $ 1,649,931
Personnel-related expenses 727,519 783,708 890,771 729,010
Non-cash stock-based compensation expenses 348,447 206,834 346,294 255,323
Supplies and materials 284,908 352,916 325,517 563,544
Facilities and other expenses 50,811 4,916 55,297 3,388
Total research and development expenses $ 2,915,250 $ 3,568,022 $ 3,363,759 $ 3,201,196

The ~~decrease~~increase in direct clinical and non-clinical expenses ~~personnel-related expenses and supplies and materials~~ was primarily due to ~~a decrease in activity~~increased activities related to the ~~impact~~MicroPine and MicroLine studies in the third quarter of 2020. The increase in personnel-related expenses was primarily due to the ~~COVID–19 pandemic~~hiring of six additional employees in the second half of 2019. The increase in facilities and ~~the resulting social distancing and shelter in place orders.~~other expenses was primarily due to increased depreciation on newly acquired assets. The increase in non-cash stock-based compensation expense was due to additional stock options that were granted subsequent to ~~June~~September 30, 2019. ~~The increase~~This was slightly offset by a decrease in ~~facilities~~supplies and ~~other expenses is~~materials due to ~~an increase~~a decrease in ~~depreciation~~spending on ~~newly acquired assets~~device inventory used in ~~addition~~clinical trials as the such trials were delayed in the first part of 2020 due to ~~an increase in travel-related expenses related to clinical studies.~~the COVID-19 pandemic.

General and Administrative Expenses

General and administrative expenses for the three months ended ~~June~~September 30, 2020 totaled ~~$2.1~~$1.7 million, an increase of ~~$0.3~~$0.2 million, or 16%, as compared to ~~$1.8~~$1.5 million recorded for the three months ended ~~June~~September 30, 2019. This increase was primarily attributable to a ~~$0.5~~$0.15 million increase in professional services related to business development ~~activities.~~activities and $0.1 million increase in patent expense and advertising and marketing as the Company increases activities to prepare for commercialization. This was slightly offset by a decrease of ~~$0.1 million in advertising and marketing and $0.1~~$0.05 million in travel expenses related to the impact of the COVID-19 pandemic.

~~Six~~Nine Months Ended ~~June~~September 30, 2020 Compared with ~~Six~~Nine Months Ended ~~June~~September 30, 2019

Research and Development Expenses

Research and development expenses for the ~~six~~nine months ended ~~June~~September 30, 2020 totaled ~~$6.5~~$9.9 million, a decrease of ~~$1.0~~$0.9 million, or ~~14%~~8%, as compared to ~~$7.6~~$10.8 million recorded for the ~~six~~nine months ended ~~June~~September 30, 2019. Research and development expenses consisted of the following:

For the Six Months Ended For the Nine Months Ended
June 30, September 30,
2020 2019 2020 2019
Direct clinical and non-clinical expenses $ 3,330,782 $ 4,409,969 $ 5,076,662 $ 6,059,900
Personnel-related expenses 1,642,668 1,524,941 2,533,439 2,253,951
Non-cash stock-based compensation expenses 655,856 900,917 1,002,150 1,156,241
Supplies and materials 782,504 732,262 1,108,021 1,295,806
Facilities and other expenses 137,727 8,829 193,024 12,216
Total research and development expenses $ 6,549,537 $ 7,576,918 $ 9,913,296 $ 10,778,114

The decrease in direct clinical and non-clinical expenses and supplies and materials was primarily due to a decrease in ~~activity~~activities related to the impact of the COVID–19 pandemic ~~and~~during the ~~resulting social distancing and shelter in place orders.~~first part of 2020. The increase in personnel-related expenses ~~and supplies and materials~~ and facilities and other expenses was primarily due to the hiring of ~~two~~six additional employees as we expanded our research and development activities for our microdose therapeutics in the second half of 2019. The decrease in non-cash stock-based compensation expense as compared to the 2019 period was primarily due to certain stock options that were accelerated and immediately vested in February 2019 slightly offset by additional options granted subsequent to ~~June~~September 30, 2019.

General and Administrative Expenses

General and administrative expenses for the ~~six~~nine months ended ~~June~~September 30, 2020 totaled ~~$3.9~~$5.7 million, an increase of ~~$0.1~~$0.5 million, or 5%8%, as compared to ~~$3.8~~$5.2 million recorded for the ~~six~~nine months ended ~~June~~September 30, 2019. This increase was primarily attributable to a $0.4 million increase in professional services related to business development activities and ~~$0.2~~$0.3 million in patent related expenses which is expected to continue to increase as programs are further developed. This was offset by a $0.3 million decrease in travel and entertainment expenses ~~and $0.2 million in contracted services and marketing~~ related to the impact of the COVID-19 pandemic.

Liquidity and Capital Resources

Since inception, we have experienced negative cash flows from operations. As of ~~June~~September 30, 2020, our accumulated deficit since inception was ~~$68.1~~$73.2 million.

As of ~~June~~September 30, 2020, we had a cash balance of ~~$10.2~~$22.9 million, working capital of ~~$8.2~~$18.6 million and stockholders’ equity of ~~$8.3~~$18.7 million. As of ~~June~~September 30, 2020 and December 31, 2019, we had ~~$0.7~~$0.6 million and $0, respectively, of debt outstanding.

~~Subsequent to June 30,~~In August 2020, we entered into athe Arctic Vision License Agreement, ~~with Arctic Vision in~~pursuant to which we received an upfront payment from Arctic Vision of $4.0 million before any payments to Senju. In addition, during the nine months ended September 30, 2020, we received approximately ~~$1.3~~$18.3 million of net proceeds from our public and private offerings, approximately $2.6 million from the exercise of warrants, ~~issued~~and approximately $0.5 million pursuant to a loan provided in ~~our private placement that closed on March 24, 2020.~~connection with the Paycheck Protection Program under the CARES Act. Subsequent to September 30, 2020, we entered into the Bausch License Agreement, pursuant to which we received an upfront payment from Bausch Health of $10.0 million.

~~These conditions raise substantial doubt about~~We expect our ~~ability~~current cash on hand to ~~continue as a going concern~~be sufficient to meet our operating and capital requirements for ~~a period of~~ at least ~~one year~~the next twelve months from the date ~~that the financial statements included elsewhere in~~of this ~~Quarterly Report on Form 10-Q are issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that~~filing. Thereafter, we may ~~be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability~~need to raise ~~additional~~further capital, through the sale of additional equity or debt securities, to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully manufacture our products and commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If ~~we are~~the Company is unable to secure additional capital, weit may be required to curtail ~~our~~its research and development initiatives and take additional measures to reduce ~~costs in order to conserve our cash.~~costs.

During the ~~six~~nine months ended ~~June~~September 30, 2020 and 2019, our sources and uses of cash were as follows:

Net cash used in operating activities for the ~~six~~nine months ended ~~June~~September 30, 2020 was ~~$9.9~~$11.9 million, which includes cash used to fund a net loss of ~~$10.5~~$15.6 million, reduced by ~~$1.3~~$1.9 million of non-cash expenses, plus ~~$0.7~~$1.8 million of cash ~~used to fund~~generated from changes in operating assets and liabilities. Net cash used in operating activities for the ~~six~~nine months ended ~~June~~September 30, 2019 was ~~$11.0~~$14.9 million, which includes cash used to fund a net loss of ~~$11.3~~$15.9 million, reduced by ~~$1.5~~$1.9 million of non-cash expenses, plus ~~$1.2~~$0.9 million of cash used to fund changes in operating assets and liabilities.

Cash used in investing activities for the ~~six~~nine months ended ~~June~~September 30, 2020 was $0.2 million, which was related to purchases of property and equipment. Cash used in investing activities for the nine months ended September 30, 2019 was less than $0.1 million, which was related to purchases of property and equipment. ~~There was no cash used in investing activities for the six months ended June 30, 2019.~~

Net cash provided by financing activities for the ~~six~~nine months ended ~~June~~September 30, 2020 totaled ~~$6.1~~$20.8 million, which was primarily attributable to aggregate net proceeds from the sale of our common stock and warrants in our ~~private placement~~public offerings of ~~$5.4~~$18.0 million, $2.6 million of proceeds from the exercise of stock warrants, and $0.5 million in proceeds from a loan in connection with the Paycheck Protection Program under the ~~Cares Act and $0.4 million of proceeds from the exercise of stock warrants.~~CARES Act. This was slightly offset by the repayment of notes payable of ~~$0.2~~$0.4 million. Cash provided by financing activities for the ~~six~~nine months ended ~~June~~September 30, 2019 totaled ~~$0.6~~$13.5 million, which was attributable to $13.0 million of aggregate net proceeds from the sale of our common stock in a public offering in July 2019 and $0.5 million of proceeds from the exercise of stock options.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

For a description of our critical accounting policies, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Recently Adopted Accounting Pronouncements

For a description of recently adopted accounting pronouncements, including adoption dates and estimated effects, if any, on our condensed financial statements, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Smaller reporting companies such as us are not required to provide the information required by this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Based on their evaluation, our principal executive officer and principal financial and accounting officer concluded that as of ~~June~~September 30, 2020 our disclosure controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures as of ~~June~~September 30, 2020.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the ~~second~~third quarter of 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Smaller reporting companies such as us are not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

Item 3. Defaults upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

21

Item 6. Exhibits.

Exhibit Incorporated by Reference (Unless Otherwise Indicated)
Number Exhibit Description Form File No. Exhibit Filing Date

10.24* Amendment to the Exclusive License Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated April 8, 2020 — — — Filed herewith
10.25 Promissory Note and Agreement dated May 3, 2020 8-K 001-38365 10.24 May 8, 2020
10.26# Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan 8-K 001-38365 10.25 July 2, 2020
10.27* Letter Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated August 10, 2020 — — — Filed herewith
10.28* License Agreement by and between Eyenovia, Inc. and Artic Vision (Hong Kong) Limited, dated August 10, 2020 — — — Filed herewith
31.1 Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
31.2 Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
32.1 Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
32.2 Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
101 Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Balance Sheets as of June 30, 2020 and December 31, 2019; (ii) Condensed Statements of Operations for the Three and Six Months Ended June 30, 2020 and 2019; (iii) Condensed Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2020 and 2019; Condensed Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019; and (iv) Notes to Condensed Financial Statements
Exhibit Incorporated by Reference (Unless Otherwise Indicated)
Number Exhibit Description Form File No. Exhibit Filing Date
10.26# Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan 8-K 001-38365 10.25 July 2, 2020
10.27* Letter Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated August 10, 2020 10-Q 001-38365 10.27 August 14, 2020
10.28* License Agreement by and between Eyenovia, Inc. and Artic Vision (Hong Kong) Limited, dated August 10, 2020 10-Q 001-38365 10.28 August 14, 2020
31.1 Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
31.2 Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
32.1 Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
32.2 Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith
101 Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Balance Sheets as of September 30, 2020 and December 31, 2019; (ii) Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2020 and 2019; (iii) Condensed Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2020 and 2019; Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019; and (iv) Notes to Condensed Financial Statements

* Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10).
# Management contract or other compensatory plan.

26
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EYENOVIA, INC.

~~August 14,~~November 12, 2020 By: /s/ John Gandolfo
John Gandolfo

Chief Financial Officer
~~(Principal~~ (Principal Financial and Accounting Officer)

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2020			2019			2020			2019

Operating Expenses:
Research and development	$	2,915,250		$	3,568,022		$	6,549,537		$	7,576,918
General and administrative		2,104,163			1,809,106			3,940,945			3,751,869


Total Operating Expenses		5,019,413			5,377,128			10,490,482			11,328,787
Loss From Operations		(5,019,413	)		(5,377,128	)		(10,490,482	)		(11,328,787	)

Other Income:
Small Business Administration Economic
Injury Disaster grant		10,000			-			10,000			-
Interest expense		(6,351	)		-			(10,032	)		-
Interest income		199			43,616			24,039			62,891

Net Loss	$	(5,015,565	)	$	(5,333,512	)	$	(10,466,475	)	$	(11,265,896	)

Net Loss Per Share
- Basic and Diluted	$	(0.25	)	$	(0.44	)	$	(0.56	)	$	(0.94	)

Weighted Average Number of
Common Shares Outstanding
- Basic and Diluted		19,821,215			12,034,450			18,563,864			11,975,035

EYENOVIA, INC.

Condensed Statements of Changes in Stockholders’ Equity
(unaudited)

	For the Six Months Ended June 30, 2020
					Additional					Total
	Common Stock				Paid-In		Accumulated			Stockholders'
	Shares		Amount		Capital		Deficit			Equity
Balance - January 1, 2020		17,100,726	$	1,710	$	69,409,949	$	(57,671,052	)	$	11,740,607

Issuance of common stock and warrants in public offering [1]		2,675,293		267		5,451,475		-			5,451,742

Stock-based compensation		-		-		583,865		-			583,865

Net loss		-		-		-		(5,450,910	)		(5,450,910	)

Balance - March 31, 2020		19,776,019		1,977		75,445,289		(63,121,962	)		12,325,304

Exercise of stock warrants		167,664		17		376,404		-			376,421

Stock-based compensation		-		-		633,146		-			633,146

Net loss		-		-		-		(5,015,565	)		(5,015,565	)

Balance - June 30, 2020		19,943,683	$	1,994	$	76,454,839	$	(68,137,527	)	$	8,319,306

	For the Six Months Ended June 30, 2019
					Additional						Total
	Common Stock				Paid-In			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity
Balance - January 1, 2019		11,468,996	$	1,147	$	53,388,216		$	(36,514,294	)	$	16,875,069

Exercise of stock options on a cashless basis		236,466		24		(24	)		-			-

Exercise of stock options		313,686		31		483,857			-			483,888

Stock-based compensation		-		-		1,032,960			-			1,032,960

Net loss		-		-		-			(5,932,384	)		(5,932,384	)

Balance - March 31, 2019		12,019,148		1,202		54,905,009			(42,446,678	)		12,459,533

Exercise of stock options		34,815		3		67,886			-			67,889

Stock-based compensation		-		-		424,019			-			424,019

Net loss		-		-		-			(5,333,512	)		(5,333,512	)

Balance - June 30, 2019		12,053,963	$	1,205	$	55,396,914		$	(47,780,190	)	$	7,617,929

EYENOVIA, INC.

Condensed Statements of Cash Flows
(unaudited)
	For the Six Months Ended
	June 30,
	2020			2019
Cash Flows From Operating Activities
Net loss	$	(10,466,475	)	$	(11,265,896	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		49,343			5,106
Stock-based compensation		1,217,011			1,456,979
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(137,187	)		(436,805	)
Accounts payable		(462,658	)		216,186
Accrued compensation		(342,967	)		(474,404	)
Accrued expenses and other current liabilities		227,795			(544,767	)
Security deposit		(1,235	)		-
Deferred rent		(6	)		3,233

Net Cash Used In Operating Activities		(9,916,379	)		(11,040,368	)

Cash Flows From Investing Activities
Purchases of property and equipment		(132,243	)		-

Net Cash Used In Investing Activities		(132,243	)		-

Cash Flows From Financing Activities
Proceeds from sale of common stock in private placement [1]		5,569,136			-
Proceeds from exercise of stock warrants		376,421			-
Proceeds from PPP 7(a) Loan		463,353			-
Repayments of notes payable		(209,324	)		-
Payment of private placement issuance costs		(117,394	)		-
Proceeds from exercise of stock options		-			551,777

Net Cash Provided By Financing Activities		6,082,192			551,777

Net Decrease in Cash and Cash Equivalents		(3,966,430	)		(10,488,591	)

Cash and cash equivalents - Beginning of Period		14,152,601			19,728,200

Cash and cash equivalents - End of Period	$	10,186,171		$	9,239,609

Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest expense	$	6,032		$	-
Income taxes	$	-		$	-

Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchase of insurance premium financed by note payable	$	(475,216	)	$	-
Exercise of stock options on a cashless basis	$	-		$	24
Deferred offering costs included in accounts payable	$	-		$	77,376

						September 30, 2020						December 31, 2019
	June 30,			December 31,		(unaudited)
	2020			2019		Current		Non-Current				Current		Non-Current
		(unaudited)				Portion		Portion		Total		Portion		Portion		Total
Paycheck Protection Program loan	$	463,353		$	-	$	39,015	$	424,338	$	463,353	$	-	$	-	$	-
Directors and officers insurance policy loan		265,892			-		106,927		-		106,927		-		-		-
		729,245			-
Less current maturities		(421,599	)		-
	$	307,646		$	-
Total						$	145,942	$	424,338	$	570,280	$	-	$	-	$	-

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value
Outstanding January 1, 2020		-		$	-
Granted		3,344,154			2.33
Exercised		(1,248,161	)		2.19
Outstanding September 30, 2020		2,095,993		$	2.41		4.0	$	1,391,817

Exercisable September 30, 2020		2,095,993		$	2.41		4.0	$	1,391,817

Warrants Outstanding			Warants Exercisable
			Weighted
	Outstanding		Average		Exercisable
Exercise	Number of		Remaining Life		Number of
Price	Warrants		In Years		Warrants
$2.0580		133,229		0.5		133,229
$2.2700		144,256		0.5		144,256
$2.4696		1,602,128		4.5		1,602,128
$2.7240		216,380		4.5		216,380
		2,095,993		4.0		2,095,993

Options Outstanding			Options Exercisable
			Weighted
	Outstanding		Average		Exercisable
Exercise	Number of		Remaining Life		Number of
Price	Options		In Years		Options
$1.24		260,000		4.5		260,000
$1.95		673,544		6.8		673,544
$2.72		764,419		-		-
$2.74		6,000		8.3		3,333
$2.89		263,500		-		-
$3.11		681,572		8.9		275,064
$3.43		58,920		-		-
$3.48		45,000		-		-
$3.71		43,000		-		-
$4.00		2,000		8.1		1,223
$4.68		25,000		-		-
$5.10		6,000		7.9		4,000
$5.19		16,500		7.9		11,000
$5.25		26,668		6.0		26,501
$6.20		311,499		7.8		265,680
$6.30		60,000		7.8		43,333
$8.72		166,918		7.5		135,101
		3,410,540		7.0		1,698,779

Exhibit		Incorporated by Reference (Unless Otherwise Indicated)
Number	Exhibit Description	Form	File No.	Exhibit	Filing Date

10.24*	Amendment to the Exclusive License Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated April 8, 2020	—	—	—	Filed herewith
10.25	Promissory Note and Agreement dated May 3, 2020	8-K	001-38365	10.24	May 8, 2020
10.26#	Eyenovia, Inc. Amended and Restated 2018 Omnibus Stock Incentive Plan	8-K	001-38365	10.25	July 2, 2020
10.27*	Letter Agreement by and between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., dated August 10, 2020	—	—	—	Filed herewith
10.28*	License Agreement by and between Eyenovia, Inc. and Artic Vision (Hong Kong) Limited, dated August 10, 2020	—	—	—	Filed herewith
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	—	—	—	Filed herewith
31.2	Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	—	—	—	Filed herewith
32.1	Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	—	—	—	Filed herewith
32.2	Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	—	—	—	Filed herewith
101	Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Balance Sheets as of June 30, 2020 and December 31, 2019; (ii) Condensed Statements of Operations for the Three and Six Months Ended June 30, 2020 and 2019; (iii) Condensed Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2020 and 2019; Condensed Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019; and (iv) Notes to Condensed Financial Statements

	EYENOVIA, INC.

~~August 14,~~November 12, 2020	By:	/s/ John Gandolfo
		John Gandolfo
		Chief Financial Officer ~~(Principal~~ (Principal Financial and Accounting Officer)